Chronic lateral epicondylitis: challenges and solutions

Wilson C Lai1
Brandon J Erickson2
Ryan A Mlynarek3
Dean Wang4
1David Geffen School of Medicine at UCLA, Los Angeles, CA, USA; 2Rothman Institute, New York, NY, USA; 3IHA Orthopaedic Specialists, Ann Arbor, MI, USA; 4Department of Orthopaedic Surgery, UC Irvine Health, Orange, CA, USA

Abstract: Lateral epicondylitis (LE) is a significant source of pain and dysfunction resulting from repetitive gripping or wrist extension, radial deviation, and/or forearm supination. Although most cases are self-limiting over several years, controversy exists regarding the best treatment strategy for chronic LE. Nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy (PT), shockwave therapy, and injections with corticosteroids or biologics are all conservative treatment options for LE. For refractory cases, surgical options include open, arthroscopic, and percutaneous techniques. In this review, the current evidence behind these treatment strategies is presented. The data demonstrate that NSAIDs, PT, bracing, and shockwave therapy provide limited benefit for treating LE. Biologics such as platelet-rich plasma and autologous whole-blood injections may be superior to steroid injections in the long-term management of LE. Although the initial results are promising, larger comparative studies on stem cell injections are needed. For refractory LE, open, arthroscopic, and percutaneous techniques are all highly effective, with no method seemingly superior over another. Arthroscopic and percutaneous approaches may result in faster recovery and earlier return to work.

Keywords: lateral epicondylitis, tennis elbow, shockwave, injection, biologics, platelet-rich plasma, stem cells, surgery

Introduction

Lateral epicondylitis (LE), or tennis elbow, affects 1%–3% of the general population each year.1–3 It is estimated that about 1 million people in the US develop new-onset LE annually.4 LE can cause significant pain and functional impairment, and despite its relatively high prevalence, there remains a myriad of treatments due to the lack of a single gold standard solution. LE produces a heavy socioeconomic burden resulting from lost workdays and may cause an inability to work for several weeks in some patients.5 Taylor and Hannafin reported that medial epicondylitis and LE accounted for 11.7% of work-related injury claims, resulting in an average direct workers' compensation cost of $6,593 per case.6

Epidemiology, pathogenesis, and natural history

LE most commonly affects adults in the fourth and fifth decade of life with men and women equally affected.7 Demographic risk factors for LE include increased age or body mass index, history of rotator cuff disease, de Quervain’s disease, carpal tunnel syndrome, and oral corticosteroid use, prior smoking history, and low social support.8,9 LE is commonly associated with overuse injury and strain from activities involving...
The most likely pathogenesis of LE is believed to be 5%-10% of patients presenting with “tennis elbow” play tennis. The most likely pathogenesis of LE is believed to be angiofibroblastic hyperplasia, characterized by Nirschl as a degenerative process in which the tendons manifest abundant fibroblastic activity, vascular hyperplasia, and unstructured collagen fibers. Rather than an inflammatory response, it is theorized that epicondylitis results from an aborted healing response to repetitive microtrauma along with vascular deprivation at the tendon origin. The degree of angiofibroblastic infiltration also appears to correlate with pain and duration of symptoms. Patients may present with a sensation of burning over the humeral insertion of the common extensor tendons. Other symptoms include loss of grip strength and pain during daily activities, such as grasping objects, turning doorknobs, and shaking hands. The majority of LE cases are self-limiting, with about 80% of patients reporting symptomatic improvement or resolution at 1 year. However, manual labor, dominant arm involvement, longer duration of symptoms with high baseline pain levels, and poor coping mechanisms are associated with a poorer prognosis. It is estimated that 3%-11% of patients eventually require operative intervention for resistant symptoms.

Knutsen et al found in a multivariate model that history of prior injection, prior orthopedic surgery, workers’ compensation claim, presence of radial tunnel syndrome, and symptoms greater than 1 year were predictors of surgical treatment.

Nonoperative treatment
Nonoperative treatment is recommended for the initial management of acute LE and include rest, nonsteroidal anti-inflammatory drugs (NSAIDs), physical therapy (PT), shockwave therapy, braces, and steroid injections. Newer biologic treatments, such as platelet-rich plasma (PRP), autologous whole-blood injections (ABIs), and stem cell therapy, are being increasingly utilized for the nonoperative treatment of LE.

NSAIDs and PT
Although NSAIDs and PT are often employed as the first-line treatment of LE, the long-term efficacy of these interventions has not been established. In a review of 15 trials by Pattanitum et al, the authors found low-quality evidence showing that topical NSAIDs were more effective than placebo alone in the short term for reducing pain, whereas the evidence on oral NSAIDs was conflicting. They concluded that there are limited data on the effectiveness of treating LE with topical or oral NSAIDs.

For the management of LE with PT, Park et al examined 31 patients with LE and found improvement in visual analog scale (VAS) pain scores with PT isometric strengthening exercises compared to no PT at 1 month follow-up. However, no differences were observed at longer follow-up (3, 6, and 12 months). Peterson et al found that in 81 patients with chronic LE lasting more than 3 months, PT resulted in faster regression of pain at 3 months follow-up than in patients who did not receive PT. However, patients were not blinded to the treatment, introducing potential bias. Coombes et al also demonstrated greater complete recovery at 4 weeks follow-up in LE patients receiving PT and placebo injection compared to those receiving placebo injection alone. The PT group also used less analgesics or anti-inflammatory medication at 1 year follow-up. Smidt et al also found that improvement with PT at 1 year follow-up was slightly better than benign neglect in a randomized controlled trial (RCT), but this difference was not statistically significant. In a large systematic review of 23 RCTs by Smidt et al, the authors concluded that there is insufficient evidence for most PT interventions for LE due to contradicting results or insufficient power in most studies. Overall, while there are some data supporting the use of PT for LE in the short term, most studies show no advantage of PT for LE in the long term.

Braces/orthoses
Commonly used braces for the treatment of LE include counterforce braces with a proximal forearm strap and wrist extension splint. The compressive force of the forearm strap limits expansion and force generated by the extensors, and the extension splint helps to relax the extensor tendons. Strujs et al observed that forearm straps alone improved daily activities at 6 weeks compared to PT or combination in 180 patients in an RCT, but no difference was observed at 6 months or 1 year. Lugribühl et al randomized 29 patients with LE into three treatment groups: forearm strap, strengthening exercises, and both. Although they noted significant symptomatic improvement in all groups over time, they found no superiority in treatment among groups at 1 year follow-up.

Shockwave therapy
Shockwave therapy has been proposed to promote tissue healing and have an analgesic effect by stimulating nerve
fibers. In two RCTs, Rompe and Pettroone and Mccall found enhanced improvements in pain and function with shockwave therapy in patients suffering from refractory LE. However, the majority of other RCTs found no difference in outcome between shockwave therapy and placebo groups. In a large systematic review, Sims et al concluded that shockwave therapy may be no more effective than placebo.

Corticosteroid injection
There are abundant data demonstrating the short-term efficacy of corticosteroid injections for the treatment of LE, but no data exist regarding their long-term efficacy. Hay et al showed that at 4 weeks, 92% of patients experienced improved or complete pain relief after a corticosteroid injection compared to 57% with naproxen only. However, no differences were found between the two groups at 1 year. Smidt et al compared the long-term outcomes after treatment with corticosteroid injection, PT, or no treatment in an RCT. They found that steroid injections and PT were more effective than no treatment before 6 weeks follow-up; however, corticosteroid injections were associated with worse outcomes at 1 year, which correlates with other reports. In a large systemic review of 10 trials by Krogh et al, the authors concluded that corticosteroid injections were no more effective than placebo beyond 8 weeks. One RCT found that the short-term benefits of corticosteroid injection were paradoxically reversed after 6 weeks, with high recurrence rates of 72% at 1 year compared to 8% after PT. Other RCTs have compared a combination of local anesthetic and corticosteroid to local anesthetic alone with conflicting results. Newcomer et al found improved VAS pain scores in the corticosteroid group between 2 and 6 months, whereas Lindenhovius et al found no difference in outcomes at 1 or 6 months follow-up. Overall, the possibility of worse long-term outcomes with corticosteroid injections, which may be attributed to weakening of the tendon, as well as the self-limiting nature of LE, has led some authors to discourage the use of corticosteroid injection for management of LE. Hence, while it seems steroid injections are effective in relieving pain from LE in the short term, there appears to be no long-lasting benefit, with a potential detriment at 1 year compared to PRP and other modalities. More research is needed on the long-term effectiveness of combined corticosteroid injection and PT.

Botulinum toxin injection
Botulinum toxin injections may help with LE by causing temporary paralysis to the extensors, preventing further microtrauma to the ECRB origin, and allowing the pathologic tissue to heal. Krogh et al reviewed four trials using botulinum toxin for LE and found marginal benefit compared to placebo, although all the studies were subjected to substantial bias and reported some cases of concomitant temporary paralysis of finger extension. Overall, the current evidence on the use of botulinum toxin is insufficient, and more studies on the optimal dosing and administration are needed.

Biologics
PRP
PRP is composed of concentrated platelets and growth factors that may induce a local healing response through cell recruitment, angiogenesis, and proliferation, although the precise mechanism remains unclear. Table 1 illustrates 17 RCTs comparing PRP injections to alternative treatments for LE. In a recent review of RCTs by Chen et al, the authors found that at both short-term and long-term follow-up, patients suffering from LE reported decreased VAS pain scores after PRP injections compared to controls. The authors concluded that PRP injections caused no significant adverse events and may result in better pain relief compared to alternative treatments. In contrast, an older review by de Vos et al found that the majority of studies showed no additional benefit of PRP compared to controls. Limitations of this study were the inclusion of a small number of studies and effect size.

PRP injection has been shown to be effective in managing chronic LE in the intermediate and long term. A recent study by Seetharamaiah et al found improved VAS pain scores for the PRP injection group at 3 and 6 months follow-up compared to the normal saline group, as well as improved pain scores at 6 months compared to the triamcinolone group. In 230 patients with symptoms for at least 3 months, Mishra et al reported that PRP treatment resulted in improved pain scores in 71.5% of patients compared to 56.1% in the control group at 24 weeks. In a systematic review, Ben-Nafa and Munro found PRP injections resulted in a more gradual pain relief that continued long term compared to corticosteroid injection. This may be due to the fact that PRP stimulates an inflammatory response and may enhance biologic healing of the diseased tendon, whereas corticosteroid can result in further degeneration of the tissue. Krogh et al showed that steroid injection decreased tendon thickness while PRP increased tendon thickness at 3 months follow-up. Although many RCTs suggest a short-term advantage with the use of corticosteroid injections compared to PRP injections, PRP injections appear to be a superior long-term treatment with benefits lasting up to 2 years or greater.
A recent study also showed that PRP injections may even reduce the need for surgical intervention.68 This has important cost-saving implications as the surgical cost for LE is estimated to be between $10,000 and $12,000.56 In a prospective RCT, Merolla et al found that PRP and arthroscopic debridement had similar effectiveness in the short and medium term; however, surgery resulted in better pain and grip strength recovery at 2 years.69 Because of the heterogeneity of PRP formulations among commercial systems, as well as the high degree of intersubject and intrasubject variability in the PRP composition produced,70 much more work is needed to determine the optimal PRP formulation (eg, high or low leukocyte concentration) that is effective in providing long-term pain relief in chronic LE.

**ABI**

ABI has been shown to be beneficial in the treatment of LE. Much like PRP, whole blood contains growth factors and cellular mediators that are thought to increase vascularity and promote healing. Another rationale for ABI is that it may induce a local pro-inflammatory response in the diseased area to promote healing.71 Some studies reported that ABI and PRP injections are equally effective in improving pain scores compared to controls.37,60,62 However, Raeissadat et al and Thanasaas et al found that PRP injections were more efficacious than ABI at 8 weeks and 6 weeks, respectively, in decreasing VAS pain scores.58,62 The results have led Thanasaas et al to conclude that PRP injection is superior to ABI for the short-term treatment of chronic or refractory LE.62

### Table 1 RCTs comparing PRP injections to alternative treatments for lateral epicondylitis

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Journal</th>
<th>Patients</th>
<th>Mean age</th>
<th>Compared to</th>
<th>Outcome in pain scores</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seetharamaiah et al63</td>
<td>2017</td>
<td>Indian Journal of Orthopedics</td>
<td>80</td>
<td>20–40</td>
<td>NS or triamcinolone</td>
<td>PRP better than steroids at 6 months. No difference at 3 months. Both better than NS group</td>
</tr>
<tr>
<td>Montalvan et al64</td>
<td>2016</td>
<td>Rheumatology</td>
<td>25</td>
<td>47</td>
<td>NS</td>
<td>PRP same as NS at 6 and 12 months</td>
</tr>
<tr>
<td>Palacio et al65</td>
<td>2016</td>
<td>Revista Brasileira de Ortopedia</td>
<td>60</td>
<td>46</td>
<td>0.3% neocaine or dexamethasone</td>
<td>PRP same as alternative treatments at 90 and 180 days</td>
</tr>
<tr>
<td>Behera et al66</td>
<td>2015</td>
<td>Journal of Orthopedic Surgery</td>
<td>25</td>
<td>38</td>
<td>Bupivacaine</td>
<td>PRP worse than bupivacaine at 1 month but superior at 6 months and 1 year</td>
</tr>
<tr>
<td>Gautam et al67</td>
<td>2015</td>
<td>Journal of Orthopedic Surgery</td>
<td>30</td>
<td>18–60</td>
<td>Corticosteroid</td>
<td>PRP superior to steroids at 6 months. No difference at 3 months</td>
</tr>
<tr>
<td>Lebiedziński et al68</td>
<td>2015</td>
<td>International Orthopedics</td>
<td>99</td>
<td>50</td>
<td>Betamethasone with lidocaine</td>
<td>PRP worse than steroid group at 6 weeks and 6 months, but better at 1 year</td>
</tr>
<tr>
<td>Tetschke et al69</td>
<td>2015</td>
<td>American Journal of Physical Medicine &amp; Rehabilitation</td>
<td>52</td>
<td>52</td>
<td>Laser</td>
<td>Laser application and PRP therapy were both effective in treating LE</td>
</tr>
<tr>
<td>Yadav et al70</td>
<td>2015</td>
<td>Journal of Clinical and Diagnostic Research</td>
<td>60</td>
<td>37</td>
<td>Methylprednisone</td>
<td>PRP group worse than steroids at 15 days and 1 month while PRP significantly better at 3 months</td>
</tr>
<tr>
<td>Mishra et al71</td>
<td>2014</td>
<td>American Journal of Sports Medicine</td>
<td>230</td>
<td>48</td>
<td>Bupivacaine</td>
<td>PRP same as bupivacaine at 12 weeks. PRP superior at 24 weeks</td>
</tr>
<tr>
<td>Raeissadat et al72</td>
<td>2014</td>
<td>Pain Research and Treatment</td>
<td>40</td>
<td>46</td>
<td>Autologous whole blood</td>
<td>PRP same as whole blood at 4 weeks, however PRP superior at 8 weeks</td>
</tr>
<tr>
<td>Raeissadat et al73</td>
<td>2014</td>
<td>BMC Sports Science, Medicine and Rehabilitation</td>
<td>67</td>
<td>44</td>
<td>Autologous whole blood</td>
<td>PRP same as whole blood at 4 and 8 weeks, and 6 and 12 months</td>
</tr>
<tr>
<td>Omar et al74</td>
<td>2012</td>
<td>The Egyptian Rheumatologist</td>
<td>30</td>
<td>38</td>
<td>Steroid</td>
<td>PRP same as steroids at 6 weeks</td>
</tr>
<tr>
<td>Creaney et al75</td>
<td>2011</td>
<td>British Journal of Sports Medicine</td>
<td>150</td>
<td>53</td>
<td>Autologous whole blood</td>
<td>PRP same as whole blood at 6 months</td>
</tr>
<tr>
<td>Gosens et al76</td>
<td>2011</td>
<td>American Journal of Sports Medicine</td>
<td>100</td>
<td>47</td>
<td>Corticosteroid</td>
<td>PRP worse at 4 weeks, but superior at 26 weeks, 1 and 2 years follow-up. No difference at 8 and 12 weeks</td>
</tr>
<tr>
<td>Thanasaas et al77</td>
<td>2011</td>
<td>American Journal of Sports Medicine</td>
<td>28</td>
<td>36</td>
<td>Autologous whole blood</td>
<td>PRP superior at 6 weeks, no difference at 3 or 6 months</td>
</tr>
<tr>
<td>Peerbooms et al78</td>
<td>2010</td>
<td>American Journal of Sports Medicine</td>
<td>100</td>
<td>47</td>
<td>Corticosteroid</td>
<td>PRP group initially worse compared to steroids, however superior at 6 months and 1 year. No differences at 1, 2, or 3 months</td>
</tr>
</tbody>
</table>

**Abbreviations:** LE, lateral epicondylitis; NS, normal saline; PRP, platelet-rich plasma; RCTs, randomized controlled trials.
Higher concentrations of growth factors in PRP compared with whole blood may explain these clinical differences. In a review of nine RCTs by Chou et al, the authors found that ABI was more effective than corticosteroid injections in relieving pain, but it was not more effective than PRP.

**Stem cells**

Stem cell therapy has been investigated as a treatment option for chronic LE. In a small study of 12 patients with chronic LE, Lee et al found that injection of allogeneic adipose-derived mesenchymal stem cells progressively improved VAS scores for up to the study’s end point at 52 weeks with no adverse events reported. In another pilot study of 12 patients, Connell et al demonstrated that an injection consisting of collagen-producing tenocyte-like cells derived from autologous skin fibroblasts resulted in clinical improvement and increased tendon thickness. Clinical improvement was observed in Patient-Rated Tennis Elbow Evaluation (PRTEE) scores at 6 weeks, 3 months, and 6 months compared to baseline, and increased thickness in tendon structure was noted on ultrasound. Of the 12 patients, 11 (91.6%) expressed satisfaction, and 10 (83.3%) noted that they would undergo the procedure again if needed. Similar findings were reported by Wang et al using autologous tenocytes derived from patellar tendon cells in a cohort of 16 patients with refractory LE. At 1 month, 3 months, 6 months, and 1 year, patients reported significantly decreased VAS pain scores, and magnetic resonance imaging showed improved tendon structure at the common extensor tendon origin. In another study, Singh et al used a bone marrow aspirate containing both PRP and mesenchymal stem cells in the treatment of LE in 30 patients. The authors found improved PRTEE scores at 2, 6, and 12 weeks after treatment. Overall, stem cell therapy may be an effective tool for patients, especially for those who have failed nonoperative treatment. However, comparative studies with larger study populations and long-term follow-up are needed before further conclusions can be drawn.

**Surgical treatment**

Surgical treatment is typically reserved for patients who experienced failure after 6–12 months of nonoperative treatment. It involves debridement of the diseased tissue within the ECRB and occasionally, the extensor digitorum communis, through open, arthroscopic, or percutaneous techniques. Controversy exists regarding the best surgical approach for treating LE. Nirschl et al were the first to report a success rate of 97.7% in 82 patients who underwent an open surgical excision and repair of the diseased ECRB along with decortication of the underlying bone. Other approaches have since been described. Using the American Board of Orthopaedic Surgery database, Wang et al reported that 92.2% and 7.8% of open and arthroscopic surgeries, respectively, were performed for LE patients by newly trained orthopedic surgeons. Percutaneous tenotomy, debridement only, and debridement with tendon repair comprised 6.4%, 46.3%, and 47.3% of open treatment, respectively.

**Open approach**

The Nirschl procedure describes excision of the area of angiofibroblastic hyperplasia and release of the common extensor origin (Figure 1). Numerous studies have demonstrated the efficacy and safety of open procedures for the treatment of LE. Dwyer et al found that greater than 95% of LE patients reported satisfaction with the open approach at 2 years follow-up. Dunn et al demonstrated sustained high long-term satisfaction rates for 44 patients, with a 97% improvement rate and a 3% rate of revision at an average of 12.6 years of follow-up after surgery. These studies support the findings that an open surgical approach is highly effective.
effective for treating refractory LE cases. Thornton et al described the addition of suture anchor repair of the ECRB tendon to the lateral epicondyle and reported increased grip and pinch strengths of 110% and 106%, respectively, when compared with the nonoperative limb. In contrast, a recent RCT by Kroslak and Murrell found no additional benefit of surgical excision of the diseased portion of ECRB over placebo surgery in a cohort of 26 patients. The authors believed that these findings may be attributed to stimulation of healing in the area, local denervation, passage of time, or the Hawthorne effect.

**Arthroscopic approach**

Benefits of the arthroscopic approach include direct visualization of the joint and ability to address concomitant intraarticular abnormalities. Baker et al performed 42 arthroscopic surgeries for LE and reported a 95% improvement at 34 months follow-up. At a mean of 130 months after surgery, VAS scores remained at 0, suggesting that the long-term benefits of arthroscopic release are sustained over time. Many studies comparing open to arthroscopic treatment have shown no significant differences in pain or function scores (Table 2). However, Peart et al reported in a cohort of 87 patients that those treated arthroscopically were able to return to work sooner. In a large review, Karkhanis et al found that the arthroscopic approach had a lower failure rate and enabled earlier return to activity compared to open techniques. In one of the largest comparative studies involving 305 patients, Solheim et al found that arthroscopic treatment resulted in a small improvement in QuickDASH (Disabilities of the arm, Shoulder and Hand) score compared to open treatment. Overall, the small number of comparative studies suggest that open and arthroscopic techniques are comparable and highly effective for treating chronic LE.

**Percutaneous approach**

Percutaneous treatment of LE has also demonstrated good results. In the study of Grundberg and Dobson, 29 out of 32 patients reported good or excellent results at an average of 26 months after surgery, with magnitude of grip strength improving 60%–90%. Dunkow et al reported greater improvement in DASH scores, patient satisfaction, and earlier return to activity in the percutaneous group compared to the open group. Othman compared arthroscopic vs percutaneous approach and found no difference in pain relief, patient satisfaction, or time to return to work at 1 year follow-up. These findings are consistent to those of Szabo et al who found no differences in recurrence rate, complication rate,

<table>
<thead>
<tr>
<th>Authors</th>
<th>Year</th>
<th>Journal</th>
<th>Patients</th>
<th>Comparisons</th>
<th>Duration of follow-up postsurgery</th>
<th>Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kwon et al</td>
<td>2017</td>
<td>Journal of Shoulder Elbow Surgery</td>
<td>55</td>
<td>Open vs arthroscopic</td>
<td>30 months</td>
<td>No significant differences in DASH and VAS scores between groups. Open Nirschl technique provides slightly superior pain relief during hard work</td>
</tr>
<tr>
<td>Solheim et al</td>
<td>2013</td>
<td>Arthroscopy</td>
<td>305</td>
<td>Open vs arthroscopic</td>
<td>Minimum 3 years follow-up</td>
<td>QuickDASH score and percentage of excellent outcomes were slightly better in the arthroscopic group</td>
</tr>
<tr>
<td>Rubenthaler et al</td>
<td>2005</td>
<td>Arthroscopy</td>
<td>30</td>
<td>Open vs arthroscopic</td>
<td>92 months</td>
<td>No differences in rating of pain, function, or complication rate</td>
</tr>
<tr>
<td>Peart et al</td>
<td>2004</td>
<td>American Journal of Orthopedics</td>
<td>87</td>
<td>Open vs arthroscopic</td>
<td>16–22 months</td>
<td>No significant difference in outcomes Patients treated with arthroscopic release returned to work earlier</td>
</tr>
<tr>
<td>Dunkow et al</td>
<td>2004</td>
<td>Journal of Bone and Joint Surgery</td>
<td>45</td>
<td>Open vs percutaneous</td>
<td>Minimum 1 year follow-up</td>
<td>Percutaneous group had better patient satisfaction, time to return to work, improvements in DASH score, and improvement in sporting activities</td>
</tr>
<tr>
<td>Szabo et al</td>
<td>2006</td>
<td>Journal of Shoulder and Elbow Surgery</td>
<td>109</td>
<td>Open vs arthroscopic vs percutaneous</td>
<td>47.8 months</td>
<td>No differences in recurrences, complications, and VAS pain scores among all groups</td>
</tr>
<tr>
<td>Othman</td>
<td>2011</td>
<td>Archives of Orthopedic and Trauma Surgery</td>
<td>33</td>
<td>Arthroscopic vs percutaneous vs percutaneous</td>
<td>10–12 months</td>
<td>Overall no difference in pain relief, satisfaction, or time to return to work in both groups</td>
</tr>
</tbody>
</table>

**Abbreviations:** DASH, Disabilities of the Arm, Shoulder and Hand; LE, lateral epicondylitis; VAS, visual analog scale.
RCTs are needed to help delineate any clinically significant approaches are highly effective in treating LE, and larger overall, the current evidence suggests that all three surgical approaches include a small population size and lack of randomization. Some of the limitations of these studies include a small population size and lack of randomization. Overall, the current evidence suggests that all three surgical approaches are highly effective in treating LE, and larger RCTs are needed to help delineate any clinically significant differences between approaches.

Summary
Current evidence suggests that NSAIDs, PT, bracing, and shockwave therapy provide limited benefit in the treatment of chronic LE. Corticosteroid injection, which was initially considered the gold standard treatment, may be effective in the short term but has diminished benefit in the long term, which may be related to structural weakening of the tendon and tenocyte inhibition. Biologic therapies, including PRP and ABI, have been shown to be more efficacious than steroids for long-term management of LE and have minimal side effects. The early studies on stem cells therapy demonstrate promising results, although comparative studies are needed. Controversy still remains regarding the best surgical approach for the management of LE. Current evidence demonstrates that open, arthroscopic, and percutaneous surgical approaches are all highly effective in treating LE. Arthroscopic and percutaneous approaches may allow for a faster recovery and earlier return to work, although more prospective RCTs and comparative cost analyses are needed.

Disclosure
The authors report no conflicts of interest in this work.

References


44. Osborne H. Stop injecting corticosteroid into patients with tennis elbow, they are much more likely to get better by themselves! *J Sci Med Sport*. 2010;13(4):380–381.


